Autophagy during hepatic stellate cell activation in alcoholic liver injury

酒精性肝损伤肝星状细胞激活过程中的自噬

基本信息

项目摘要

DESCRIPTION (provided by applicant): Progressive hepatic fibrosis and cirrhosis leading to end-stage liver disease are major consequences of chronic alcohol abuse that cost thousands of lives, and hundreds of millions of dollars in health care costs. Despite the clear link between alcohol, fibrosis and end-stage liver disease, there are no approved antifibrotic therapies that can delay disease progression or forestall complications of fibrosis, and thus progress is urgently needed. The hepatic stellate cell (HSC), following activation during alcoholic liver injury, plays a central role in the development of fibrosis. Our long-term goal is to understand how HSC activation is stimulated in response to alcohol; progress will lead to novel, targeted interventions for alcoholic liver disease. A study published by others describing loss of lipid droplets as a feature of autophagy sparked our idea that autophagy is a component of HSC activation. Autophagy is a highly regulated cellular response that has evolved to maintain energy homeostasis during cellular stress or enhanced metabolic demand, and its features remarkably parallel those of HSC activation. The objective of this project, which is the next step towards our long-term goal, is to characterize the contribution of autophagy to HSC activation in alcoholic liver injury. Our central hypothesis, therefore, is that autophagy is a critical and necessary component of HSC activation in alcoholic fibrosis. We will test our central hypothesis through the following interrelated Specific Aims: 1. Define stimuli associated with alcoholic liver injury that provoke autophagy in HSCs, by using ethanol-specific culture models of HSC activation in which autophagy will be documented by: Western blot to detect conversion of LC3-I protein to LC3-II, ultrastructure, and reduced lipid content. 2. Determine which features of autophagy during HSC activation in vivo are alcohol-dependent by characterizing the response to siRNA knockdown of Atg7 or Atg5 in HSCs from ethanol-fed mice, and define autophagy-regulated pathways by quantitative PCR and Western for known activation markers, and exon arrays for novel targets. 3. Establish the dependence of alcohol-related HSC activation on autophagy in vivo by blocking autophagy in alcohol-fed mice. These studies should uncover fundamental new pathways of stellate cell activation specifically related to alcohol's effects in the liver, leading to innovative treatment approaches for patients with alcoholic liver disease.
描述(由申请人提供):渐进的肝纤维化和肝硬化导致终末期肝病是慢性酒精滥用的主要后果,造成了数千人的生命,以及数亿美元的医疗保健费用。尽管酒精,纤维化与终末期肝病之间存在明确的联系,但尚无批准的抗纤维化疗法,可以延迟疾病进展或纤维化的预防并发症,因此迫切需要进展。酒精肝损伤期间激活后,肝星状细胞(HSC)在纤维化发展中起着核心作用。我们的长期目标是了解如何响应饮酒而刺激HSC激活。进展将导致针对酒精性肝病的新颖,有针对性的干预措施。其他人发表的一项描述脂质液滴损失为自噬特征的研究激发了我们的想法,即自噬是HSC激活的组成部分。自噬是一种高度调节的细胞反应,已在细胞应激或代谢需求增强的过程中演变为维持能量稳态,其特征显着平行于HSC激活。该项目的目的是朝着我们的长期目标迈出的下一步,是表征自噬对酒精肝损伤中HSC激活的贡献。因此,我们的中心假设是自噬是酒精纤维化中HSC激活的关键和必要组成部分。我们将通过以下相互关联的特定目的来检验中心假设:1。通过使用HSC激活的乙醇特异性培养模型来定义与酒精性肝损伤相关的刺激,从而引起自噬,其中自噬将记录在以下情况下:Western blot检测LC3-I蛋白对LC3-I蛋白质对LC3-II的转化,并改进了LC3-I蛋白质,并改进了LC3-I的lip Ipditive lips contive lips contive lips contive contuds contive intuds contive and red Ipditive。 2.通过表征来自乙醇喂养的小鼠的HSC的siRNA敲低ATG7或ATG5的响应,确定体内HSC激活期间自噬的哪些特征依赖于酒精,并通过定量PCR定义了自动噬菌体调节的途径,用于已知的激活标记,以及用于新型目标的Exon Actional阵列。 3。通过阻断酒精喂养小鼠的自噬来确定与酒精相关的HSC激活对自噬的依赖性。这些研究应揭示与酒精在肝脏中的作用特别相关的星状细胞激活的基本途径,从而为酒精性肝病患者提供创新的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT L. FRIEDMAN其他文献

SCOTT L. FRIEDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT L. FRIEDMAN', 18)}}的其他基金

Training Program in Investigative Gastroenterology and Hepatology
胃肠病学和肝病学研究培训计划
  • 批准号:
    10628499
  • 财政年份:
    2023
  • 资助金额:
    $ 36.99万
  • 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10350710
  • 财政年份:
    2021
  • 资助金额:
    $ 36.99万
  • 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10182514
  • 财政年份:
    2021
  • 资助金额:
    $ 36.99万
  • 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10597033
  • 财政年份:
    2021
  • 资助金额:
    $ 36.99万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10666671
  • 财政年份:
    2020
  • 资助金额:
    $ 36.99万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10547688
  • 财政年份:
    2020
  • 资助金额:
    $ 36.99万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10011650
  • 财政年份:
    2020
  • 资助金额:
    $ 36.99万
  • 项目类别:
Liver Cancer (LC) (Project-003)
肝癌 (LC)(项目-003)
  • 批准号:
    8932193
  • 财政年份:
    2015
  • 资助金额:
    $ 36.99万
  • 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
  • 批准号:
    8334729
  • 财政年份:
    2011
  • 资助金额:
    $ 36.99万
  • 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
  • 批准号:
    8504895
  • 财政年份:
    2011
  • 资助金额:
    $ 36.99万
  • 项目类别:

相似国自然基金

神经元缺血性"程序性坏死"调控机制及3-methyladenine保护机制研究
  • 批准号:
    81100877
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation
量化 NNK 代谢物以促进 Kava 肺癌预防临床转化
  • 批准号:
    10512091
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
  • 项目类别:
Targeting NOX4-dependent mitochondrial dysfunction, autophagy and defective calcium handling in AF
针对 AF 中 NOX4 依赖性线粒体功能障碍、自噬和钙处理缺陷
  • 批准号:
    10540353
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
  • 项目类别:
Developing a genetic tag for in vivo protein regulation using PROTACs with companion PET imaging
使用 PROTAC 和伴随 PET 成像开发用于体内蛋白质调节的遗传标签
  • 批准号:
    10535045
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
  • 项目类别:
Targeting NOX4-dependent mitochondrial dysfunction, autophagy and defective calcium handling in AF
针对 AF 中 NOX4 依赖性线粒体功能障碍、自噬和钙处理缺陷
  • 批准号:
    10392272
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
  • 项目类别:
Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation
量化 NNK 代谢物以促进 Kava 肺癌预防临床转化
  • 批准号:
    10683294
  • 财政年份:
    2022
  • 资助金额:
    $ 36.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了